# Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

> **NCT03868722** · PHASE2,PHASE3 · RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 212 (estimated)

## Conditions studied

- CLL

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03868722
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-11
- **Primary completion:** 2029-07-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2023-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868722, "Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03868722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*